Anavex Life Sciences Corp (AVXL)

[Gernee20]

I agree. I don't think it was strictly because of the dosing. I do think it could have something to do with how they want data to read, and that could tie into dosing changes. You're right, too many possibilities. Common sense tells me just by looking on the surface, the separate trial Is dose optimized. The adaptive trial allowed for individual patient dose optimization, while this separate ph2b continuation trial could be dose optimized. This would allow new baseline, and new data from zero without readout containing data from the previous year with some patients on dosing which was below therapeutic benefit. In short, we simply have a fresh sleight.